Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

Rhea-AI Summary

Medicenna Therapeutics Corp. (MDNA) announces its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023, while continuing to trade on the Toronto Stock Exchange under its symbol MDNA. The OTCQB is the primary platform for U.S. and international companies in the entrepreneurial and development stages, providing a high-quality trading and information experience for U.S. investors.

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023. Medicenna’s shares will continue to trade on the Toronto Stock Exchange under its symbol MDNA.

The OTCQB stands as the primary platform for U.S. and international companies in the entrepreneurial and development stages, dedicated to delivering a high-quality trading and information experience for their U.S. investors. Streamlined market standards enable Canadian companies to provide a strong baseline of transparency to inform and engage U.S. investors. To be eligible, companies must maintain up-to-date financial reporting, meet a minimum bid price threshold, and undergo a semiannual process of company verification and management certification.

About Medicenna

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class empowered superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) with no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.

For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

Investor and Media Contacts

Christina Cameron
Investor Relations, Medicenna Therapeutics
ir@medicenna.com

Investor Contact
Argot Partners
Phone: 212-600-1902
medicenna@argotpartners.com 

FAQ

When will Medicenna Therapeutics Corp. shares commence trading on the OTCQB Venture Market?

Medicenna Therapeutics Corp. shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023.

What is the ticker symbol for Medicenna Therapeutics Corp. on the Toronto Stock Exchange?

The ticker symbol for Medicenna Therapeutics Corp. on the Toronto Stock Exchange is MDNA.

What are the eligibility requirements for companies to trade on the OTCQB Venture Market?

Companies must maintain up-to-date financial reporting, meet a minimum bid price threshold, and undergo a semiannual process of company verification and management certification to be eligible to trade on the OTCQB Venture Market.